Navigation Links
Laureate Pharma Welcomes Three New Members to Business Development Team
Date:11/2/2009

PRINCETON, N.J., Nov. 2 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and manufacture of monoclonal antibody products, fusion proteins and other recombinant protein products, today announced the addition of three new members to its Business Development team. "We're delighted to have three new team members with such extensive experience and expertise in outsourcing services and customer support joining our team," said Dan Leone, Vice President, Business Development. "We will have two team members covering eastern US/Canada and one covering western US/Canada."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

Andrew Arrage joins Laureate as Director, Business Development - East. Andrew has over 15 years of experience and a proven track record in the biopharmaceutical services industry, delivering services to clients in the biotech and pharmaceutical industries.

Patricia Caplan joins Laureate as Director, Business Development - East. Patricia brings more than 20 years of experience working with clients to develop their therapeutic protein products and move them from the bench into the clinic and on to commercialization.

Bruce Frazier joins Laureate as Manager, Business Development - West. Bruce, who most recently worked in business development at a biopharmaceutical services company, has applied his experience as a quality control skilled scientist to become an accomplished business development professional dedicated to serving clients requiring biopharmaceutical testing and manufacturing services.

"Andrew, Patricia and Bruce add great depth and valuable experience to our business development team," said Robert J. Broeze, Ph.D., President and CEO of Laureate. "With their strong customer service and project management skills they will play a key role in expanding Laureate's portfolio of client projects and providing critical support to our customer base."

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert: For information on the listed expert, click appropriate link.

Robert Broeze

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360

SOURCE Laureate Pharma, Inc.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Reuters Predicts Nobel Laureates
2. Laureate Pharma Elects New Board Member
3. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
4. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
5. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
6. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
7. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Laureate Announces Manufacturing Agreement with Tolerx
10. Laureate Pharma to Add More Manufacturing Capacity
11. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... 2017 , ... Each year, Crain’s Detroit Business News ranks the most innovative ... patent estate of a company, its impact and significance, and the likelihood of bringing ... in technologies that transform energy sources such as low dose X-ray and convert them ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PORTLAND, Oregon and Pune, India , January 12, 2017 ... In vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis ... reach $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase ... show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ ... treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
Breaking Biology News(10 mins):